Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Ptc Therapeutics (PTCT) Operating Expenses (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Operating Expenses data on record, last reported at $236.0 million in Q4 2025.

  • For Q4 2025, Operating Expenses fell 37.15% year-over-year to $236.0 million; the TTM value through Dec 2025 reached $525.9 million, down 52.59%, while the annual FY2025 figure was $863.7 million, 22.14% down from the prior year.
  • Operating Expenses reached $236.0 million in Q4 2025 per PTCT's latest filing, up from $84.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $423.4 million in Q2 2023 and bottomed at $84.0 million in Q3 2025.
  • Average Operating Expenses over 5 years is $266.9 million, with a median of $251.3 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: surged 64.16% in 2023, then plummeted 66.55% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $250.0 million in 2021, then surged by 47.13% to $367.8 million in 2022, then fell by 18.09% to $301.2 million in 2023, then grew by 24.67% to $375.6 million in 2024, then plummeted by 37.15% to $236.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $236.0 million in Q4 2025, $84.0 million in Q3 2025, and $205.9 million in Q1 2025.